Literature DB >> 10479175

Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity.

I M Nilsson1, M Verdrengh, R G Ulrich, S Bavari, A Tarkowski.   

Abstract

Staphylococcal exotoxins are virulence determinants in Staphylococcus aureus arthritis and septicemia. To assess the utility of enterotoxins as vaccine candidates for these diseases, a genetically modified staphylococcal enterotoxin A (SEA) that lacks superantigenic properties was used. Mice immunized with recombinant (r) SEA had significantly longer survival than control immunized mice and lost significantly less weight than the controls. Transfer of SEA-specific antibodies to naive mice resulted in good protection against death in staphylococcal sepsis. In vitro proliferative responses to SEA by naive lymphocytes were almost totally abolished on incubation with serum from rSEA but not with control antigen-immunized mice. These results suggest that immunization with rSEA devoid of superantigenic properties provides good protection against S. aureus sepsis. In addition, the data indicate that the protection is at least in part mediated by SEA neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479175     DOI: 10.1086/315023

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha.

Authors:  Heike I Krupka; Brent W Segelke; Robert G Ulrich; Sabine Ringhofer; Mark Knapp; Bernhard Rupp
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Authors:  O Zachrisson; P Colque-Navarro; C G Gottfries; B Regland; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

4.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

5.  Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.

Authors:  R D LeClaire; S Bavari
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Antibody responses in patients with invasive Staphylococcus aureus infections.

Authors:  G Jacobsson; P Colque-Navarro; E Gustafsson; R Andersson; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-10       Impact factor: 3.267

7.  Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.

Authors:  Tomás Maira-Litrán; Andrea Kropec; Donald A Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  Development of Antistaphylococcal Vaccines.

Authors:  Jean C. Lee
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

9.  Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant Staphylococcus aureus.

Authors:  Michael S Calderwood; Christopher A Desjardins; George Sakoulas; Robert Nicol; Andrea Dubois; Mary L Delaney; Ken Kleinman; Lisa A Cosimi; Michael Feldgarden; Andrew B Onderdonk; Bruce W Birren; Richard Platt; Susan S Huang
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

10.  Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients.

Authors:  Agnieszka Dryla; Sonja Prustomersky; Dieter Gelbmann; Markus Hanner; Edith Bettinger; Béla Kocsis; Tamás Kustos; Tamás Henics; Andreas Meinke; Eszter Nagy
Journal:  Clin Diagn Lab Immunol       Date:  2005-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.